apocell Home Contact Us

Illuminating biomarker detection – Leading the way in personalized medicine.

David B. McWilliams Novelos Therapeutics, Inc.
Chairman of the Board

David McWilliams has served as Director since 2004. From 2004 to 2008 Mr. McWilliams served as president and chief executive officer of Opexa. In 2003, Mr. McWilliams served as president and chief executive officer of Bacterial Barcodes, Inc., a molecular diagnostics company. Mr. McWilliams currently serves as a director of Novelos Therapeutics, Inc., and on the boards of ApoCell Biosciences and Norwell, a cancer therapeutic company. Mr. McWilliams received an MBA in finance from the University of Chicago and a B.A. in chemistry, Phi Beta Kappa, from Washington and Jefferson College.

Thomas H. Jennings Summit Partners

Thomas Jennings has served as Director since 2009. Mr. Jennings is Managing Director at Summit Partners, whom he joined in 1997. Prior to Summit, he worked as a consultant with Andersen Consulting (now Accenture). Mr. Jennings has served as a director of numerous software, technology, healthcare and life sciences companies. He is currently a director of ApoCell, AvePoint, Fermentas and Telerik. He is actively involved with Summit’s investments in IMMCO Diagnostics, NameMedia and NetWitness Corporation. Mr. Jennings holds an AB in economics and theology from Boston College, where he received the Scholar of the College award.

William J. Dore’ Jr.

William J. Dore’, Jr., has served as a Director since 2005. From 2000 to 2006, Mr. Dore’ served as Vice President, Investor Relations at Global Industries, Ltd., overseeing capital fund raising activities, communications to the investment community and corporate communications, including marketing. Mr. Dore’ has spent that past 20 years in the oil services sector including serving on the executive management team for Dore’ Energy Corporation. Mr. Dore’ currently operates a private equity fund and serves on various corporate boards.

Rick L. Ryan

Rick Ryan has been in the Biotech/Life Science industry for 30 years. Rick was the Vice President of the Drug Discovery & Development business unit at Millipore from 2006-2010, where he was responsible for the development and commercialization of products and services [both new chemical entities and biotherapeutics] for biopharma customers. He also led cross-divisional innovation initiatives to support the development of biomarkers and stem cells for drug discovery/development applications. He was formerly the President of LINCO Research Inc, which was acquired by Serologicals in May 2006, followed immediately by Millipore’s acquisition in July, 2006. For the 20 years prior to LINCO and Millipore, Rick held several technology and business management positions at Embrex (VP Commercial Development; animal vaccines) , Purina Mills (VP Biotechnology Development) and Monsanto Company. During his 15 years at Monsanto he held several positions, including Dir. Commercial/Business Development, Dir. Strategic Planning and Dir. International Markets. Rick received his PhD (Biochemistry) from the University of Illinois and his MBA from Washington University.He retired from Millipore in Dec 2010, and recently formed The Winfield Group, a life sciences consulting firm with a focus on strategic development of new technology and services for biopharma and biomedical applications.

Scientific Advisor

David J. McConkey, Ph.D. The University of Texas M.D. Anderson Cancer Center

David McConkey is a Professor of Urology and Cancer Biology and Director of Urological Research at the University of Texas M.D. Anderson Cancer Center. Dr. McConkey is interested in identifying the molecular mechanisms that block physiological cell death (“apoptosis”) in cancer cells, with an emphasis on bladder, prostate, and pancreatic cancers, and determining the effects of investigational cancer therapies on apoptosis in preclinical models of human cancer. Dr. McConkey is best known for his work with proteasome inhibitors, growth factor receptor antagonists, TNF-related apoptosis-inducing ligand (TRAIL), and anti-angiogenic agents, and he has published over 150 papers in peer-reviewed journals and is on the editorial boards of Clinical Cancer Research, The Journal of Biological Chemistry, and Cancer Biology and Therapy.